239 related articles for article (PubMed ID: 20418886)
1. PU.1-mediated upregulation of CSF1R is crucial for leukemia stem cell potential induced by MOZ-TIF2.
Aikawa Y; Katsumoto T; Zhang P; Shima H; Shino M; Terui K; Ito E; Ohno H; Stanley ER; Singh H; Tenen DG; Kitabayashi I
Nat Med; 2010 May; 16(5):580-5, 1p following 585. PubMed ID: 20418886
[TBL] [Abstract][Full Text] [Related]
2. MOZ-TIF2-induced acute myeloid leukemia requires the MOZ nucleosome binding motif and TIF2-mediated recruitment of CBP.
Deguchi K; Ayton PM; Carapeti M; Kutok JL; Snyder CS; Williams IR; Cross NC; Glass CK; Cleary ML; Gilliland DG
Cancer Cell; 2003 Mar; 3(3):259-71. PubMed ID: 12676584
[TBL] [Abstract][Full Text] [Related]
3. Ring1A and Ring1B inhibit expression of Glis2 to maintain murine
Shima H; Takamatsu-Ichihara E; Shino M; Yamagata K; Katsumoto T; Aikawa Y; Fujita S; Koseki H; Kitabayashi I
Blood; 2018 Apr; 131(16):1833-1845. PubMed ID: 29371181
[TBL] [Abstract][Full Text] [Related]
4. MOZ fusion proteins in acute myeloid leukaemia.
Troke PJ; Kindle KB; Collins HM; Heery DM
Biochem Soc Symp; 2006; (73):23-39. PubMed ID: 16626284
[TBL] [Abstract][Full Text] [Related]
5. MOZ is critical for the development of MOZ/MLL fusion-induced leukemia through regulation of Hoxa9/Meis1 expression.
Katsumoto T; Ogawara Y; Yamagata K; Aikawa Y; Goitsuka R; Nakamura T; Kitabayashi I
Blood Adv; 2022 Oct; 6(19):5527-5537. PubMed ID: 35947126
[TBL] [Abstract][Full Text] [Related]
6. Bromodomain-PHD finger protein 1 is critical for leukemogenesis associated with MOZ-TIF2 fusion.
Shima H; Yamagata K; Aikawa Y; Shino M; Koseki H; Shimada H; Kitabayashi I
Int J Hematol; 2014 Jan; 99(1):21-31. PubMed ID: 24258712
[TBL] [Abstract][Full Text] [Related]
7. Essential role of PU.1 in maintenance of mixed lineage leukemia-associated leukemic stem cells.
Aikawa Y; Yamagata K; Katsumoto T; Shima Y; Shino M; Stanley ER; Cleary ML; Akashi K; Tenen DG; Kitabayashi I
Cancer Sci; 2015 Mar; 106(3):227-36. PubMed ID: 25529853
[TBL] [Abstract][Full Text] [Related]
8. MOZ-TIF2 inhibits transcription by nuclear receptors and p53 by impairment of CBP function.
Kindle KB; Troke PJ; Collins HM; Matsuda S; Bossi D; Bellodi C; Kalkhoven E; Salomoni P; Pelicci PG; Minucci S; Heery DM
Mol Cell Biol; 2005 Feb; 25(3):988-1002. PubMed ID: 15657427
[TBL] [Abstract][Full Text] [Related]
9. MOZ-TIF2 repression of nuclear receptor-mediated transcription requires multiple domains in MOZ and in the CID domain of TIF2.
Yin H; Glass J; Blanchard KL
Mol Cancer; 2007 Aug; 6():51. PubMed ID: 17697320
[TBL] [Abstract][Full Text] [Related]
10. Expression of the MOZ-TIF2 oncoprotein in mice represses senescence.
Largeot A; Perez-Campo FM; Marinopoulou E; Lie-a-Ling M; Kouskoff V; Lacaud G
Exp Hematol; 2016 Apr; 44(4):231-7.e4. PubMed ID: 26854485
[TBL] [Abstract][Full Text] [Related]
11. Protein kinase A inhibition of macrophage maturation is accompanied by an increase in DNA methylation of the colony-stimulating factor 1 receptor gene.
Zasłona Z; Scruggs AM; Peters-Golden M; Huang SK
Immunology; 2016 Oct; 149(2):225-37. PubMed ID: 27353657
[TBL] [Abstract][Full Text] [Related]
12. STAT5 is crucial to maintain leukemic stem cells in acute myelogenous leukemias induced by MOZ-TIF2.
Tam WF; Hähnel PS; Schüler A; Lee BH; Okabe R; Zhu N; Pante SV; Raffel G; Mercher T; Wernig G; Bockamp E; Sasca D; Kreft A; Robinson GW; Hennighausen L; Gilliland DG; Kindler T
Cancer Res; 2013 Jan; 73(1):373-84. PubMed ID: 23149921
[TBL] [Abstract][Full Text] [Related]
13. Roles of the histone acetyltransferase monocytic leukemia zinc finger protein in normal and malignant hematopoiesis.
Katsumoto T; Yoshida N; Kitabayashi I
Cancer Sci; 2008 Aug; 99(8):1523-7. PubMed ID: 18754862
[TBL] [Abstract][Full Text] [Related]
14. MOZ-TIF2 alters cofactor recruitment and histone modification at the RARbeta2 promoter: differential effects of MOZ fusion proteins on CBP- and MOZ-dependent activators.
Collins HM; Kindle KB; Matsuda S; Ryan C; Troke PJF; Kalkhoven E; Heery DM
J Biol Chem; 2006 Jun; 281(25):17124-17133. PubMed ID: 16613851
[TBL] [Abstract][Full Text] [Related]
15. Heterozygous PU.1 mutations are associated with acute myeloid leukemia.
Mueller BU; Pabst T; Osato M; Asou N; Johansen LM; Minden MD; Behre G; Hiddemann W; Ito Y; Tenen DG
Blood; 2002 Aug; 100(3):998-1007. PubMed ID: 12130514
[TBL] [Abstract][Full Text] [Related]
16. A novel fusion between MOZ and the nuclear receptor coactivator TIF2 in acute myeloid leukemia.
Carapeti M; Aguiar RC; Goldman JM; Cross NC
Blood; 1998 May; 91(9):3127-33. PubMed ID: 9558366
[TBL] [Abstract][Full Text] [Related]
17. MOZ is essential for maintenance of hematopoietic stem cells.
Katsumoto T; Aikawa Y; Iwama A; Ueda S; Ichikawa H; Ochiya T; Kitabayashi I
Genes Dev; 2006 May; 20(10):1321-30. PubMed ID: 16702405
[TBL] [Abstract][Full Text] [Related]
18. MOZ/TIF2-induced acute myeloid leukaemia in transgenic fish.
Zhuravleva J; Paggetti J; Martin L; Hammann A; Solary E; Bastie JN; Delva L
Br J Haematol; 2008 Nov; 143(3):378-82. PubMed ID: 18729850
[TBL] [Abstract][Full Text] [Related]
19. Transcriptional mechanisms that control expression of the macrophage colony-stimulating factor receptor locus.
Rojo R; Pridans C; Langlais D; Hume DA
Clin Sci (Lond); 2017 Aug; 131(16):2161-2182. PubMed ID: 28760770
[TBL] [Abstract][Full Text] [Related]
20. Acute mixed lineage leukemia with an inv(8)(p11q13) resulting in fusion of the genes for MOZ and TIF2.
Liang J; Prouty L; Williams BJ; Dayton MA; Blanchard KL
Blood; 1998 Sep; 92(6):2118-22. PubMed ID: 9731070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
